- Home
- CTOR vs MCRB Comparison
CTOR vs MCRB Comparison
Compare CTOR & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- MCRB
- Stock Information
- Founded
- CTOR 2021
- MCRB 2010
- Country
- CTOR United States
- MCRB United States
- Employees
- CTOR N/A
- MCRB N/A
- Industry
- CTOR
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- CTOR
- MCRB Health Care
- Exchange
- CTOR NYSE
- MCRB Nasdaq
- Market Cap
- CTOR 126.2M
- MCRB 142.0M
- IPO Year
- CTOR N/A
- MCRB 2015
- Fundamental
- Price
- CTOR $1.55
- MCRB $1.05
- Analyst Decision
- CTOR Strong Buy
- MCRB Buy
- Analyst Count
- CTOR 1
- MCRB 4
- Target Price
- CTOR $6.00
- MCRB $4.17
- AVG Volume (30 Days)
- CTOR 87.9K
- MCRB 3.7M
- Earning Date
- CTOR 08-12-2024
- MCRB 10-31-2024
- Dividend Yield
- CTOR N/A
- MCRB N/A
- EPS Growth
- CTOR N/A
- MCRB N/A
- EPS
- CTOR N/A
- MCRB N/A
- Revenue
- CTOR N/A
- MCRB $374,000.00
- Revenue This Year
- CTOR N/A
- MCRB N/A
- Revenue Next Year
- CTOR N/A
- MCRB N/A
- P/E Ratio
- CTOR N/A
- MCRB N/A
- Revenue Growth
- CTOR N/A
- MCRB N/A
- 52 Week Low
- CTOR $1.53
- MCRB $0.54
- 52 Week High
- CTOR $49.00
- MCRB $2.78
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- MCRB 56.67
- Support Level
- CTOR N/A
- MCRB $0.91
- Resistance Level
- CTOR N/A
- MCRB $1.14
- Average True Range (ATR)
- CTOR 0.00
- MCRB 0.13
- MACD
- CTOR 0.00
- MCRB 0.03
- Stochastic Oscillator
- CTOR 0.00
- MCRB 50.91
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.